2016 (23 POSTS)

Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA. 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5.

View Abstract

Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA, Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208.

View Abstract

Erichsen R, Kelsh MA, Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503.

View Abstract

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M, et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311. PMID: 27587380.

View Abstract

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.

View Abstract

Panko JM, Benson SM, Kreider ML. Meta-analysis of lung cancer risk related to diesel exposure by occupation and evaluation of exposure response. Abstract #2976. Poster at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

View Abstract

Lancet JE, Sacks NC, Cyr PL, Chiarella MT, Louie AC, Cortes JE. VYXEOS™ (CPX-351) increases event-rree survival and time spent out of the hospital in acute myeloid leukemia patients, compared with 7+3 standard of care. Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco CA, April 2016.

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. Hospitalizations for older patients with acute myeloid leukemia (AML): High costs and long stays, with and without chemotherapy. Academy Health Annual Research Meetings, Boston, MA, 2016.

Pierce JS, Ruestow PS, Finley BL. 2016. An updated evaluation of reported no-observed adverse effect levels for chrysotile asbestos for lung cancer and mesothelioma. Crit Rev Toxicol 46(7):561-586; doi: 10.3109/10408444.2016.1150960.

View Abstract

Sacks NC, Cyr P, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Burden of acute myeloid leukemia (AML) among older newly-diagnosed patients. Blood 128(22):4780; doi: 10.1182/blood.V128.22.4780.4780.

View Abstract

Sacks NC, Noone J, Cyr PL, Miller DJ, Chiarella MT, Louie AC. 2016. Hospitalizations for older patients with acute myeloid leukemia (AML): Inpatient treatment is intensive and costly. Value in Health 19(3):A246; doi: 10.1016/j.jval.2016.03.1051.

View Abstract

Sacks NC, Sharma A, Cyr PL, Liu Y, Miller DJ, Chiarella MT, Louie AC. 2016. Outcomes for older patients with acute myeloid leukemia (AML): Multiple hospitalizations and high mortality rates. Value in Health 19(7):A611; doi: 10.1016/j.jval.2016.09.1523.

View Abstract

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Poster presentation at American Industrial Hygiene Conference & Exposition (AIHce), 2016.

Suh M, Thompson CM, Brorby GP, Mittal L, Proctor DM. 2016. Inhalation cancer risk assessment of cobalt metal. Regul Toxicol Pharm 79(Aug):74-82; doi: 10.1016/j.yrtph.2016.05.009.

View Abstract

Pierce JS, Ruestow PS, Finley BL. An updated evaluation of reported chrysotile asbestos no observed adverse effect levels (NOAELs) for lung cancer and mesothelioma. Abstract #2139. Poster presentation at Society of Toxicology 55th Annual Meeting, New Orleans, LA, 2016.

Benson SM, Batdorf S, Hitchcock KM, Galbraith DA, Finley BL. Asbestos exposure and pharyngeal and laryngeal cancer risk: A fiber-type specific meta-analysis. Abstract #2974. Poster presentation at Society of Toxicology 55th Annual Meeting, New Orleans, LA, 2016.

Proctor DM. Cancer risk assessment for ingested hexavalent chromium: Challenges and controversies – Introduction. [session introduction; no abstract]. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

Wikoff D, Borghoff SJ, Rager JE, Haws LC. Human relevance assessment of tetrabromobisphenol-A (TBBPA) induced uterine adenocarcinomas: Mode of action dependent on high dose molecular initiating event (MIE). Presented in the “Flame Retardants” session at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

View Abstract

Suh M, Crump K, Mittal L, Hirsch S, Valdes Salgado R, Bartlett C, Van Landingham C, Rohr A, Proctor DM. Inhalation cancer risk assessment of hexavalent chromium based on updated mortality for Painesville chromate production workers. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

View Abstract

Brorby GP, Suh M, Thompson CM, Mittal L, Proctor DM. Inhalation cancer risk assessment of cobalt metal. Presented at Society of Toxicology 55th Annual Meeting, New Orleans, LA, March 2016.

View Abstract